A Single-Center, Double-Blind, Placebo-Controlled, Phase 1a, Fed-Fasted, Crossover Study To Investigate The Safety, Tolerability, Pharmacokinetics, And Food Effects Of A Single Oral Dose Of EC5026 In Healthy Male And Female Subjects
Latest Information Update: 23 Feb 2024
At a glance
- Drugs EC 5026 (Primary)
- Indications Pain
- Focus Adverse reactions; Pharmacokinetics
- Sponsors EicOsis
- 17 Feb 2024 Status changed from recruiting to completed.
- 04 Jun 2021 New trial record